Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 1/20 | 0.40 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 4/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 2/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | CASP1 | P29466 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.30 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.30 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5006019 | 0.77 | PNMT (0.35) | — | |
| SCHEMBL558657 | 0.77 | MEN1 (0.38) | GABRA1GABRB2MEN1KMT2AALDH1A1 | |
| SCHEMBL5067880 | 0.71 | GABRA1 (0.41) | GABRA1GABRB2MEN1KMT2AL3MBTL1 | |
| SCHEMBL11498977 | 0.71 | GABRA1 (0.41) | GABRA1GABRB2MEN1KMT2AL3MBTL1 | |
| SCHEMBL10411212 | 0.70 | — | — | |
| SCHEMBL14696799 | 0.69 | PSMB8 (0.55) | GABRA1GABRB2MEN1KMT2AL3MBTL1 | |
| SCHEMBL2360344 | 0.69 | GABRA1 (0.46) | GABRA1GABRB2MEN1KMT2AL3MBTL1 | |
| SCHEMBL28532339 | 0.69 | GABRA1 (0.39) | GABRA1GABRB2MEN1KMT2AL3MBTL1 | |
| SCHEMBL3798167 | 0.69 | GABRA1 (0.39) | GABRA1GABRB2MEN1KMT2AL3MBTL1 | |
| SCHEMBL9412069 | 0.69 | ALDH1A1 (0.51) | GABRA1GABRB2MEN1KMT2AL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2855471-B1 | QUINUCLIDINE, 1-AZABICYCLO[2.2.1]HEPTANE, 1-AZABICYCLO [3.2.1]OCTANE, and 1-AZABICYCLO[3.2.2]NONANE COMPOUNDS AS ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | BRISTOL MYERS SQUIBB CO (US) | 2017-11-15 | — | — | EP | claimed |
| US-20150322089-A1 | QUINUCLIDINE, 1-AZABICYCLO[2.2.1]HEPTANE, 1-AZABICYCLO [3.2.1]OCTANE, and 1-AZABICYCLO[3.2.2]NONANE COMPOUNDS AS ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-11-12 | — | — | US | claimed |
| EP-2855471-A1 | QUINUCLIDINE, 1-AZABICYCLO[2.2.1]HEPTANE, 1-AZABICYCLO [3.2.1]OCTANE, and 1-AZABICYCLO[3.2.2]NONANE COMPOUNDS AS ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | Bristol-Myers Squibb Company (US) | 2015-04-08 | — | — | EP | claimed |
| WO-2013177024-A1 | QUINUCLIDINE, 1-AZABICYCLO[2.2.1]HEPTANE, 1-AZABICYCLO [3.2.1]OCTANE, and 1-AZABICYCLO[3.2.2]NONANE COMPOUNDS AS ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-11-28 | — | — | WO | claimed |
| US-8455866-B2 | Heterocyclic compound and organic light-emitting device including the same | SAMSUNG DISPLAY CO., LTD. (KR) | 2013-06-04 | — | — | US | claimed |
| US-8384074-B2 | Heterocyclic compound and organic light-emitting device including the same | SAMSUNG DISPLAY CO., LTD. (KR) | 2013-02-26 | — | — | US | claimed |
| US-20110240978-A1 | HETEROCYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME | SAMSUNG MOBILE DISPLAY CO., LTD (KR) | 2011-10-06 | — | — | US | claimed |
| US-20110240977-A1 | HETEROCYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME | SAMSUNG MOBILE DISPLAY CO., LTD. (KR) | 2011-10-06 | — | — | US | claimed |
| US-7544808-B2 | Tricyclic modulators of the glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-06-09 | — | — | US | claimed |
| EP-1703797-A4 | TRICYCLIC MODULATORS OF THE GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NF-kappaB ACTIVITY AND USE THEREOF | BRISTOL MYERS SQUIBB CO (US) | 2009-01-14 | — | — | EP | claimed |
| EP-1703797-A2 | TRICYCLIC MODULATORS OF THE GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NF-κB ACTIVITY AND USE THEREOF | Bristol-Myers Squibb Company (US) | 2006-09-27 | — | — | EP | claimed |
| CN-1738814-A | Indolyl pyrazinone derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis | BAYER PHARMACEUTICALS CORP (US) | 2006-02-22 | — | — | CN | claimed |
| US-6995181-B2 | Modulators of the glucocorticoid receptor and method | BRISTOL-MYERS SQUIBB CO. (US) | 2006-02-07 | — | — | US | claimed |
| US-6969728-B2 | Antiinflammatory agents | GENZYME CORPORATION (US) | 2005-11-29 | — | — | US | claimed |
| US-20050187242-A1 | Tricyclic modulators of the glucocorticoid receptor, AP-1, and/or NF-kB activity and use thereof | BRISTOL-MYERS SQUIBB COMPANY | 2005-08-25 | — | — | US | claimed |
| WO-2005072132-A2 | TRICYCLIC MODULATORS OF THE GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NF-κB ACTIVITY AND USE THEREOF | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-08-11 | — | — | WO | claimed |
| US-20050171136-A1 | Modulators of the glucocorticoid receptor and method | VACCARO WAYNE (US) | 2005-08-04 | — | — | US | claimed |
| EP-1534273-A2 | MODULATORS OF THE GLUCOCORTICOID RECEPTOR AND METHOD | Bristol-Myers Squibb Company (US) | 2005-06-01 | — | — | EP | claimed |
| US-20040132758-A1 | Modulators of the glucocorticoid receptor and method | BRISTOL-MYERS SQUIBB COMPANY | 2004-07-08 | — | — | US | claimed |
| WO-2004009017-A2 | MODULATORS OF THE GLUCOCORTICOID RECEPTOR AND METHOD | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-01-29 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110240978-A1 | HETEROCYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME | LEF1, IDO1, NOD1 | GABRA1 4608/4885GABRB2 4853/4885MEN1 630/4885 |
| US-20110240977-A1 | HETEROCYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME | IDO1, LEF1, TPH1 | GABRA1 4603/4885GABRB2 4850/4885MEN1 659/4885 |
| US-20050187242-A1 | Tricyclic modulators of the glucocorticoid receptor, AP-1, and/or NF-kB activity and use thereof | NFRKB, NFKBIA, NFKB1 | GABRA1 990/4885GABRB2 1004/4885MEN1 4388/4885 |
| US-20150322089-A1 | QUINUCLIDINE, 1-AZABICYCLO[2.2.1]HEPTANE, 1-AZABICYCLO [3.2.1]OCTANE, and 1-AZABICYCLO[3.2.2]NONANE COMPOUNDS AS ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | CHRNA7, CHRNA2, CHRNA1 | GABRA1 244/4885GABRB2 334/4885MEN1 3177/4885 |
| US-20040132758-A1 | Modulators of the glucocorticoid receptor and method | NR3C1, NR3C2, MC2R | GABRA1 237/4885GABRB2 254/4885MEN1 4737/4885 |
| US-20050171136-A1 | Modulators of the glucocorticoid receptor and method | NR3C1, MC2R, NR3C2 | GABRA1 342/4885GABRB2 389/4885MEN1 4667/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.